Articles On Dimerix (ASX:DXB)

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

ASX health stocks fall in past five days in line with broader markets as investors spooked by hotter than expected inflation Dimerix up 33% for week after inking second exclusive license deal for commercialisation of its Phase 3 kidney dis...

Dimerix (ASX:DXB) has announced an exclusive license agreement with Taiba Middle East for the commercialisation of its candidate DMX-200.

The ASX200 closed the day up 0.8%. All sectors bar one finished in the green. Real-estate lead the way, up 1.8%, tele-communications and staples followed, both gaining around 1.3%. The energy sector was the only sector to fall short,...

ASX in broad rebound; Cettire, Neuren, and Lendlease lead surge Positive sentiment follows Wall Street strength DY6 Metals up 300pc on  Rare Earths find at the Tundulu project in Malawi   Aussie shares rebounded pretty much across the boa...

The ASX200 is trading up around 0.7 per cent. Most sectors are in the green, real estate has gained the most so far, up nearly 1.6%. Staples follows, up 1.2%. The utilities and energy sectors are the only two to slip into the red....

Dimerix sells exclusive rights to register and commercialise DMX-200 for the treatment of kidney disease in key Middle East countries Dimerix to receive up to ~$120.5m from Taiba in upfront and milestone payments, plus royalties Second dea...

EMVision’s AI algorithm shows promise EMvision Medical Devices (ASX:EMV) has shared an update from its ongoing clinical trials focusing on improving EMVision’s AI algorithms for diagnosing strokes caused by bleeding or blockages in the brai...

Last Monday marked Clinical Trials Day, when the world’s healing profession celebrated the work of Royal Navy surgeon James Lind. The medical mariner was credited with carrying out the world’s first placebo-controlled clinical trial in 1747...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

The ASX has plunged alongside Wall Street on jitters of higher US rates for longer All 11 sectors closed in the red Uranium stocks gathered some ground today   The ASX200 has tumbled over 1% on Wednesday as hot US labour data sent jitters...

UK Regulatory Agency has given the greenlight for Dimerix’s DMX-200 Paediatric Investigation Plan The UK Paediatric Investigation Plan aims to ensure sufficient data is generated in Dimerix’s ACTION Phase 3 trial to allow for marketing app...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Morgans says economic challenges have been catalyst for innovation and resilience in ASX health sector PharmAust submits supplementary data to US FDA from Phase 1 MEND study in support of its ODD request Singular health gets $1 million bac...

Morgans says more money could flow into ASX healthcare sector in 2024 as higher interest rate cycle stabilises Nyrada soars after lead drug candidate demonstrates strong efficacy in reducing secondary brain injury in animal study   Dimerix...

Dimerix (ASX:DXB) has announced it has received firm commitments to raise $20 million via an institutional placement with proceeds to complete the ACTION3 Phase 3 clinical study in patients with debilitating kidney disease.

  Local markets gives up early gains, ekes out 0.1pc advantage IT and Utilities offset by Energy sector losses Small Caps led by RMI and Narryer Metals   We’re slightly higher at match out in Sydney. But big banks became bad banks after l...

Dimerix secures firm commitments for a $20m institutional placement ‘Highly strategic’ capital raise will see new institutional investors join the company’s register Proceeds will be used to advance the ACTION3 Phase 3 trial of DMX-200 in...

Dimerix Ltd (ASX: DXB) shares are taking off on Tuesday. In morning trade, the ASX healthcare stock is up 20% to a 52-week high of 36 cents. Why is this ASX healthcare stock jumping? The catalyst for this rise has been the successful compl...

Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB), just announced success on its interim Phase III clinical trial for FSGS - a rare kidney disease.

  Local markets get smashed, drop 1.8pc All 11 ASX sectors down Small Caps led by Task Group   A record close on Friday has found a typically ASX200-flavoured follow-up on Monday after the last session in New York saw US semiconductor dar...

  Dimerix ACTION3 Phase 3 trial successfully passes first interim analysis using proteinuria efficacy endpoint DMX-200 performing better than placebo in reducing proteinuria in patients with FSGS The trial’s IDMC says it has no safety conc...

Dimerix ACTION3 Phase 3 trial successfully passes first interim analysis endpoint Mesoblast says US FDA supports accelerated approval pathway for rexlemestrocel-L Imexhs raises $1.5 million in cap raise to sophisticated and institutional i...

There’s expected to be a more lacklustre session on the ASX200, after last week’s record-breaking performances. Futures tips the market will be down around about a half a per cent. US markets lost their steam on Friday and that saw te...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Local markets end slightly higher IT Sector slumps 1.2pc Small Caps led by AT1   The ASX 200 traded sideways again today, closing the day +0.1% higher as gains in Financials and Real Estate were offset by losses in Tech and Mining stocks....

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

  Local markets end +0.13% higher in quasi-comeback Consumer Staples soar on bumper Coles news, but offset by everyone else Small Caps led by Audeara on the back of a massive manufacturing sale   The indignation of Coles has led Consumer...

Dimerix (ASX:DXB) has announced that data from the first 72 patients randomised in the ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis has successfully been collected.

Dimerix first analysis results of Phase III trial into focal segmental glomerulosclerosis (FSGS) due in March Results are key milestone for Dimerix which has been working on its lead asset DMX-200 since around 2012 Dimerix finalised its fi...

  ASX200 drops about 0.7pc on Wednesday Consumer Staples craters, as WOW CEO departs Small Caps led by diggers IXR, AW1 and the biopharma Alterity   The ASX200 has ended lower on Wednesday, tracking losses in New York as traders brace – a...

Dimerix receives approval of investigational new drug application for ACTION3 trial in China No bridging studies required in the Chinese population prior to recruitment for trial Dimerix says the milestone approval may support partnering d...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, that made announcements today.   ICYMI Leade...

Dimerix (ASX:DXB) secures approval from the Chinese NMPA Centre for Drug Evaluation (CDE) for its IND application The approval greenlights the recruitment of 70 clinical sites across 11 countries, with further expansion plans post the an...

Dimerix (ASX:DXB) has announced that Chinese National Medical Products Administration Center for Drug Evaluation has approved an Investigational New Drug application to commence recruitment for ACTION3 Phase 3 study of DMX-200 for f...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Australian company Dimerix (ASX:DXB) has received an initial payment of €6.5 million ($10.7 million) from its partner, UK-based Advanz Pharma.

Dimerix (ASX:DXB) receives an initial upfront payment of €6.5 million (A$10.7 million) from Advanz Pharma As part of the agreement, Advanz has been granted rights to market DMX-200 for FSGS within the European Economic Area, the UK, Swit...

Shares in All Ordinaries Index (ASX: XAO) stock Pacific Current Group Ltd (ASX: PAC) have jumped more than 8% today on takeover news related to GQG Partners Inc (ASX: GQG). Pacific Current owns stakes in fund managers from around the world...

The S&P ASX 200 fell -3.8% in October with mid-caps falling -6.94% and small-caps down -5.45% for the month S&P ASX 200 Energy was the only sector that closed October in the black with all Australian equity factors in red Dimerix...

Share prices are always changing on the stock market, so different opportunities are opening up. A fund manager has highlighted two All Ordinaries Index (ASX: XAO) shares that could be very appealing to investors. The fund manager in quest...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Investors are always warned to be careful, or even suspicious, of high dividend yields. That's because lofty yields can easily be a trap, where a declining share price ends up cancelling out all the received distributions — or worse. So wh...

Ask any chief of a development-stage biotech about the prospect of a partnering or licencing deal and they will refer to a multitude of discussion with big pharma – all couched in suitably vague terms. But when Dimerix (ASX:DXB) chief Dr Ni...

ASX 200 closes higher for a fifth straight day All 11 Sectors make it home for supper Small caps led by Zuleika and Creasy   It’s fair to say the little battler of an Aussie sharemarket’s put in a real decent day’s work. As various part...

This week’s Bulls N’ Bears top ASX runner is… Noxopharm. It skyrocketed 323 per cent to join other impressive runners including Dimerix, Roots Sustainable Agricultural Technologies and Toys“R”Us.

Benchmark index finishes Friday ahead +0.4% Sectors led by Financials Small caps dominated by Dimerix   The ASX200 is up +0.4% at  the end of Friday trade, making the week a 1% loss, which we’ll take at this stage. US equities ticked l...

Investing in bonds is a topic that has been growing in interest in recent months. With inflation remaining stubbornly sticky in most advanced economies, compounded by rising oil prices, fears that interest rates may not have peaked just ye...